证券代码：688067 证券简称：爱威科技 公告编号：2025-048 爱威科技股份有限公司 2025年前三季度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》的有关规定，上市公司回购专用账户中的股份，不享有股东会 表决权、利润分配、公积金转增股本、认购新股和可转换公司债券等权利。故公 司回购专用证券账户持有股份不参与本次利润分配。 重要内容提示： | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/12/5 | 2025/12/8 | 2025/12/8 | 一、 通过分配方案的股东会届次和日期 本次利润分配方案经爱威科技股份有限公司（以下简称"公司"）2025 年 5 月 23 日的2024年年度股东会授权，2025 年 10 月 29 日召开的第五届董事会第六 次会议审议通过。 二、 分配方案 1. 发放年度：2025年前三季度 2. 分派对象： 截至股权 ...

Core Viewpoint - The company emphasizes its commitment to research and development (R&D), indicating a 7.28% year-on-year increase in R&D investment for the first three quarters of 2025, despite a slight decrease in the proportion of R&D investment to revenue due to overall revenue growth [1] Group 1 - The company has maintained an R&D investment revenue ratio above 10% since its listing [1] - Future plans include continuing high-intensity R&D investments to enhance core competitiveness [1]

Group 1 - The core viewpoint of the news is that Aiwei Technology has shown a slight increase in stock price and has reported significant financing activities, indicating investor interest despite a low financing balance relative to market value [1] - As of November 14, Aiwei Technology's financing balance is 40.86 million yuan, accounting for 2.09% of its market capitalization, which is below the 50th percentile level over the past year, indicating a low financing position [1] - The company has not engaged in any short selling activities on November 14, with a short selling balance of 0, which is at a high level compared to the 90th percentile over the past year [1] Group 2 - As of September 30, Aiwei Technology reported a total of 4,350 shareholders, an increase of 6.46% from the previous period, while the average circulating shares per person decreased by 6.07% [2] - For the period from January to September 2025, Aiwei Technology achieved operating revenue of 171 million yuan, representing a year-on-year growth of 11.63%, and a net profit attributable to shareholders of 29.24 million yuan, up 16.35% year-on-year [2] - Since its A-share listing, Aiwei Technology has distributed a total of 40.73 million yuan in dividends, with 20.33 million yuan distributed over the past three years [3]

Policy Developments - Jiangxi Province is promoting the development of brain-computer interface medical devices, emphasizing the need for regulatory compliance and collaboration among industry players to seize opportunities in emerging technologies [1] - The market for brain-computer interface medical devices is noted to have significant potential, with a strong development momentum in Jiangxi Province [1] Medical Device Approvals - In October, the National Medical Products Administration approved 204 medical device products, including 173 domestic Class III devices, 10 imported Class III devices, and 21 imported Class II devices [2] Pharmaceutical Logistics - The Shanghai Municipal Drug Administration encourages the development of modern pharmaceutical logistics, advocating for improved storage and management systems to enhance operational efficiency and reduce costs [3] Drug Approvals - Fangsheng Pharmaceutical announced that its Indobufen tablets received a drug registration certificate from the National Medical Products Administration, allowing for production [4] - Saito Bio's application for the chemical raw material drug Mometasone Furoate has been approved, indicating its use in treating asthma and skin conditions [5] - Tianyao Pharmaceutical received a drug registration certificate for Metoclopramide injection, which is used for treating nausea and vomiting [6] Capital Market Activities - Yingsi Intelligent submitted a listing application to the Hong Kong Stock Exchange, aiming to raise funds for its AI-driven drug development initiatives [7][8] - Rejuve Bio plans to repurchase shares worth between 100 million and 200 million yuan to support employee stock ownership plans [9] Industry Developments - AstraZeneca's Baxdrostat demonstrated significant reductions in 24-hour average systolic blood pressure in treatment-resistant hypertension patients during the Bax24 Phase III trial, achieving a reduction of 14.0 mmHg compared to placebo [10][11] - The drug showed good overall tolerability and consistent safety profiles, with a notable percentage of patients achieving target blood pressure levels [11] - Maiwei Bio's IL-11 monoclonal antibody 9MW3811 received approval for Phase II clinical trials targeting pathological scars, marking it as the first IL-11 targeted drug to enter clinical trials for this indication [12] - Aiwei Technology's subsidiary obtained a medical institution practice license, enabling it to provide third-party medical testing services [13] - Anke Bio signed an exclusive agency framework agreement with Boshengji for the PA3-17 injection product, aimed at enhancing its product portfolio in the innovative drug market [14][15]

Core Viewpoint - Awei Technology Co., Ltd. has announced that its wholly-owned subsidiary, Hunan Awei Medical Testing Co., Ltd., has obtained a medical institution practice license, allowing it to provide third-party medical testing services, which is expected to create a new growth point for the company [1][2]. Group 1: License Acquisition - Hunan Awei Medical Testing Co., Ltd. received the medical institution practice license from the Health and Health Bureau of Hunan Xiangjiang New District [1]. - The license is valid from November 4, 2025, to November 3, 2030, and covers various diagnostic specialties including clinical microbiology and clinical chemistry [1]. Group 2: Impact on Business - The acquisition of the license enables the company to integrate its existing testing instruments and reagents with testing services, promoting a "device + service" business model [2]. - The impact on the company's performance post-launch of the testing laboratory remains uncertain due to factors such as industry supply and demand, market competition, and brand promotion [2]. Group 3: Investor Communication - The company will hold a third-quarter performance briefing on November 24, 2025, to discuss its operational results and financial status, allowing investors to engage in Q&A [6][7]. - Investors can submit questions from November 17 to November 21, 2025, through the Shanghai Stock Exchange Roadshow Center [8].

Core Points - Awei Technology announced that its wholly-owned subsidiary, Hunan Awei Medical Laboratory Co., Ltd., has received a medical institution practice license from the Health Bureau of Hunan Xiangjiang New Area [2] Group 1 - The license allows the subsidiary to operate as a medical institution, which may enhance its service offerings and market presence [2]

证券代码：688067 证券简称：爱威科技 公告编号：2025-047 爱威科技股份有限公司 关于子公司取得医疗机构执业许可证的 自愿性披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 有效期限：自 2025 年 11 月 04 日至 2030 年 11 月 03 日 诊疗科目：医学检验科；临床体液、血液专业；临床微生物学专业；临床化 学检验专业；临床免疫、血清学专业；临床细胞分子遗传学专业******。 二、本次获证对公司的影响 本次湖南爱威医学检验所有限公司获得医疗机构执业许可证，未来将正式对 外提供第三方医学检验服务。这不仅为公司开辟了新的业务增长点，更有助于将 公司现有的检验仪器、试剂耗材与检验服务深度融合，打造"设备+服务"一体化 的商业模式。 爱威科技股份有限公司（以下简称"公司"）全资子公司湖南爱威医学检验 所有限公司于近日收到湖南湘江新区管理委员会卫生健康局签发的《中华人民共 和国医疗机构执业许可证》。现将相关事项公告如下： 一、执业证书主要内容 机构名称：长沙爱威医学检验实验室 地 址：湖南省长沙 ...

证券代码：688067 证券简称：爱威科技 公告编号： 2025-046 爱威科技股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： （二） 会议召开地点：上海证券交易所上证路演中心 会议召开时间：2025 年 11 月 24 日 （星期一） 15:00-16:00 会议召开地点：上海证券交易所上证路演中心（网址：https://roadshow.ssei nfo.com/） 会议召开方式：上证路演中心网络互动 （三） 会议召开方式：上证路演中心网络互动 三、 参加人员 董事长、总经理：丁建文先生 董事、副总经理：林常青先生 独立董事：张颖先生 董事会秘书：袁绘杰先生 投资者可于 2025 年 11 月 17 日 （星期一） 至 11 月 21 日 （星期五）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司投资者关系邮箱 aveir@c-ave.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 爱威科技股份有 ...

Core Viewpoint - Aiwei Technology (688067.SH) has received a medical institution practice license for its wholly-owned subsidiary, Hunan Aiwei Medical Laboratory Co., Ltd., allowing it to officially provide third-party medical testing services, which opens new business growth opportunities and integrates existing testing instruments and reagents with testing services into a "device + service" business model [1]. Company Summary - Hunan Aiwei Medical Laboratory Co., Ltd. has obtained the "Medical Institution Practice License" issued by the Health and Health Bureau of Hunan Xiangjiang New Area [1]. - The licensed diagnostic specialties include: medical laboratory, clinical body fluids and blood, clinical microbiology, clinical chemical testing, clinical immunology and serology, and clinical cellular molecular genetics [1]. - The new license enables the company to offer third-party medical testing services, enhancing its business model by integrating testing equipment and services [1].

Core Viewpoint - Aiwei Technology (688067.SH) has received a medical institution practice license for its wholly-owned subsidiary, Hunan Aiwei Medical Laboratory Co., Ltd, enabling it to provide third-party medical testing services, which will create new business growth opportunities and integrate existing testing instruments and reagents with testing services into a "device + service" business model [1] Group 1 - The company has obtained a medical institution practice license from the Hunan Xiangjiang New Area Health Bureau [1] - Hunan Aiwei Medical Laboratory Co., Ltd will officially offer third-party medical testing services [1] - This development is expected to open new business growth points for the company [1] Group 2 - The integration of existing testing instruments and reagents with testing services will enhance the company's offerings [1] - The company aims to create a comprehensive "device + service" business model [1]